Clinical Trials Database Auditors Wary Of Liability Risk, GSK Attorney Says
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline is having difficulty finding independent auditors willing to take the responsibility for confirming the contents of the company's clinical trial results database, U.S. VP-R&D Legal Operations Tom Merchant says
You may also be interested in...
FDA ClinicalTrials.gov Report Will Show Growing Rate Of Study Listings
The forthcoming report also will show increased disclosure of company sponsors and drug names in trial descriptions. FDA has added language to IND acknowledgement letters to promote compliance with listing requirements.
FDA ClinicalTrials.gov Report Will Show Growing Rate Of Study Listings
The forthcoming report also will show increased disclosure of company sponsors and drug names in trial descriptions. FDA has added language to IND acknowledgement letters to promote compliance with listing requirements.
GSK Settles With N.Y.; Company Will Post Past Trial Data By End Of 2005
The settlement includes a modest $2.5 mil. disgorgement fee. GSK is also required to advertise the clinical trial register in seven prominent peer reviewed journals.